Form 4: Heartflow CMO Exercises Stock Options
Statement of Changes in Beneficial Ownership
Chief Medical Officer Campbell Rogers exercised 10,000 stock options at a price of $2.22 per share.
Summary
- Campbell Rogers, Chief Medical Officer of Heartflow, Inc., exercised 10,000 stock options on June 15, 2026.
- The exercise was conducted at a strike price of $2.22 per share.
- Following the transaction, the reporting person holds 88,731 shares directly.
- The transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on December 12, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine, pre-planned transaction by an executive rather than a strategic shift or market-moving disclosure.
Positives
- The transaction demonstrates executive participation in the company's equity incentive program.
- The use of a Rule 10b5-1 plan indicates a structured, pre-planned approach to equity management, reducing concerns regarding insider trading.
Negatives
- None identified.
Risks
- The reporting person's continued service is required for the vesting of remaining derivative securities.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the reporting of insider equity transactions.
Industry Context
StockSavvy.ai notes that routine option exercises by C-suite executives under 10b5-1 plans are standard corporate governance practices and generally do not signal a change in management's outlook on the company's long-term prospects.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is a standard industry practice for executives to manage personal liquidity while maintaining compliance with SEC regulations.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was pre-planned and represents a standard exercise of compensation-related equity.
Next Steps
- Continued vesting of remaining derivative securities through July 1, 2027.
Key Dates
| Date | Description |
|---|---|
| 2025-12-12 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-06-15 | Date of the option exercise transaction. |
| 2026-06-17 | Date the Form 4 was signed and filed. |
| 2027-07-01 | Final vesting date for remaining stock options. |
| 2033-07-10 | Expiration date for the stock options. |
Keywords
Heartflow, HTFL, Insider Trading, Form 4, Stock Options, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.